Marvel withdraws biosimilar insulins as EU bioequivalence rules evolve
This article was originally published in Scrip
Marvel BioSciences has hit another hitch in its efforts to get its biosimilar insulin onto the EU market, after it withdrew approval applications for three products that were under evaluation by the European Medicines Agency.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.